- Case-Based Modules
- Initial Evaluation
- Dermatologic Manifestations
- Oral Manifestations
- OIs: Prophylaxis
- OIs: Treatment
- Antiretroviral Rx
- Antiretroviral Rx: Resistance
- Antiretroviral Rx: Adverse Effects
- Drug-Drug Interactions
- Postexposure Prophylaxis
- Perinatal Transmission
- Special Populations
- Prevention for Positives
- Challenging Unknowns
- Resource-Limited Settings
- Interactive Tutorials
- Routine HIV Screening
- Oraquick Advance Rapid HIV Test
- HIV Integration
- This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.
Antiretroviral Rx
Question | Discussion | References | CME Credit
Case 2: Antiretroviral Regimens
You answered:
 |
Tenofovir-emtricitabine (Truvada) plus lopinavir-ritonavir (Kaletra) |
|---|
This answer is incorrect. This combination of drugs is not considered a preferred regimen because lopinavir-ritonavir is no longer a preferred protease inhibitor, except when used in pregnant women in combination with zidovudine-lamivudine.
Choose another answer:
Copyright © 2004-2013 University of Washington